

# Information for Connecticut Prescribers of Prescription Drugs

## Cymbalta® (duloxetine delayed-release capsule)

- Connecticut Public Act No. 23-171 requires “pharmaceutical representatives” (as defined in the Act) provide certain information to prescribers and pharmacists. The information in this disclosure is being provided pursuant to this Act.
- Lilly USA LLC's Wholesale Acquisition Cost (WAC) is the listed price to the distribution channel not including prompt pay, service or administrative fees, stocking or distribution allowances, or any discounts, rebates, or chargebacks provided by Lilly USA to any entity.

### **Product:**

BRAND NAME	GENERIC NAME	STRENGTH	DOSAGE FORM	PACK SIZE	NDC	WHOLESALE ACQUISITION COST <sup>1</sup>
Cymbalta®	duloxetine delayed-release capsules	20 mg	Capsule	60	0002-3235-60	\$500.40
		30 mg	Capsule	30	0002-3240-30	\$280.50
		30 mg	Capsule	90	0002-3240-90	\$841.50
		60 mg	Capsule	30	0002-3270-30	\$280.50

In adults with major depressive disorder, analyses of the relationship between treatment outcome and race did not suggest any differential responsiveness to Cymbalta® (duloxetine delayed-release capsules) on the basis of these patient characteristics.<sup>2</sup>

See [Prescribing Information](#), including Boxed Warnings.

Cymbalta® is a registered trademark owned or licensed by Eli Lilly and Company, its subsidiaries or affiliates.

<sup>1</sup> Source: AnalySource®. Accessed on 01/01/2023. WAC reprinted with permission by First Databank Inc. All rights reserved. © 2023. <http://www.fdbhealth.com/policies/drug-pricing-policy/>.

<sup>2</sup> US Cymbalta Prescribing Information.